Comparative Pharmacology
Head-to-head clinical analysis: NORQUEST FE versus YASMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORQUEST FE versus YASMIN.
NORQUEST FE vs YASMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins, inhibiting ovulation. Drospirenone has antimineralocorticoid activity, reducing water retention, and antiandrogenic activity.
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
One tablet (ethinyl estradiol 0.03 mg / drospirenone 3 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Terminal elimination half-life is approximately 30 hours for drospirenone; steady-state concentration is achieved after 10 days of daily dosing.
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Approximately 40% renal and 60% fecal after oral administration; metabolites are excreted as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive